Affiliation: Mayo Clinic
- Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifenXianglin Wu
Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1stStreet SW, Rochester, MN 55905, USA
Breast Cancer Res 13:R27. 2011..Here, we characterize the molecular actions of endoxifen in breast cancer cells expressing ERβ and examine its effectiveness as an anti-estrogenic agent in these cell lines...
- Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogensJohn R Hawse
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA
PLoS ONE 8:e54613. 2013....
- The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cellsXianglin Wu
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Res 69:1722-7. 2009..These results support the theory that endoxifen is the primary metabolite responsible for the overall effectiveness of tamoxifen in the treatment of ER-positive breast cancer...
- Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibodyXianglin Wu
Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA
J Cell Biochem 113:711-23. 2012..The use of the MC10 antibody, in combination with highly specific antibodies targeting only full-length ERβ, is likely to provide additional discriminatory features in breast cancers that may be useful in predicting response to therapy...